MMA Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

MMA Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,931	Closed	-$203K	–	115
2023 Q1	$203K	Hold	2,931	–	–	0.15%	100
2022 Q4	$211K	Sell	2,931 -1,785	-38%	-$135K	0.17%	98
2022 Q3	$335K	Sell	4,716 -1,386	-23%	-$101K	0.29%	61
2022 Q2	$470K	Hold	6,102	–	–	0.4%	50
2022 Q1	$466K	Buy	+6,102	New	+$410K	0.37%	52

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MMA Asset Management's BMY Position: Q2 2023 in Review

MMA Asset Management sold out of Bristol-Myers Squibb (BMY) in Q2 2023, closing a stake of 2,931 shares — an estimated $203K sold.

MMA Asset Management first reported a position in BMY in Q1 2022 and held it in 5 quarters. The position peaked at $470K in Q2 2022. 2,480 funds tracked by Wall St. Rank hold BMY as of Q2 2023.

MMA Asset Management reported no remaining Bristol-Myers Squibb position as of Q2 2023 after selling out during the quarter.
MMA Asset Management sold 2,931 Bristol-Myers Squibb shares in Q2 2023, an estimated $203K.
MMA Asset Management first reported a position in Bristol-Myers Squibb in Q1 2022 and held it in 5 quarters.
MMA Asset Management's Bristol-Myers Squibb position peaked at $470K in Q2 2022.
2,480 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.

Based on MMA Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.